Concord Biotech Ltd
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]
- Market Cap ₹ 17,428 Cr.
- Current Price ₹ 1,666
- High / Low ₹ 1,815 / 952
- Stock P/E 55.4
- Book Value ₹ 146
- Dividend Yield 0.53 %
- ROCE 27.9 %
- ROE 20.9 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 20.9%
Cons
- Stock is trading at 11.4 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|
340 | 436 | 512 | 617 | 713 | 853 | 1,017 | 1,038 | |
195 | 256 | 308 | 289 | 439 | 509 | 585 | 597 | |
Operating Profit | 145 | 180 | 205 | 328 | 274 | 344 | 432 | 441 |
OPM % | 43% | 41% | 40% | 53% | 38% | 40% | 42% | 42% |
18 | 17 | 31 | 14 | 23 | 35 | 34 | 37 | |
Interest | 1 | 1 | 1 | 1 | 6 | 5 | 3 | 2 |
Depreciation | 18 | 19 | 21 | 28 | 50 | 54 | 54 | 54 |
Profit before tax | 144 | 178 | 213 | 313 | 241 | 320 | 409 | 422 |
Tax % | 30% | 33% | 21% | 25% | 26% | 26% | 26% | |
100 | 118 | 169 | 235 | 179 | 238 | 305 | 314 | |
EPS in Rs | 105.66 | 124.48 | 177.65 | 247.44 | 187.76 | 22.76 | 29.13 | 30.07 |
Dividend Payout % | 0% | 21% | 22% | 0% | 3% | 30% | 30% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 18% |
3 Years: | 18% |
TTM: | 20% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | 9% |
TTM: | 29% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 71% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 19% |
Last Year: | 21% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 585 | 673 | 761 | 990 | 1,098 | 1,282 | 1,515 |
22 | 9 | 52 | 89 | 62 | 32 | 10 | |
69 | 72 | 118 | 94 | 144 | 191 | 164 | |
Total Liabilities | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 |
189 | 230 | 240 | 546 | 573 | 593 | 575 | |
CWIP | 3 | 19 | 141 | 18 | 74 | 173 | 211 |
Investments | 151 | 229 | 199 | 142 | 74 | 138 | 244 |
343 | 285 | 361 | 477 | 592 | 611 | 668 | |
Total Assets | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
79 | 155 | 167 | 207 | 246 | 265 | ||
-42 | -114 | -195 | -112 | -158 | -155 | ||
-37 | -43 | 31 | -100 | -85 | -99 | ||
Net Cash Flow | 0 | -1 | 3 | -4 | 3 | 12 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 236 | 133 | 131 | 105 | 119 | 117 | 125 |
Inventory Days | 381 | 310 | 312 | 503 | 434 | 430 | 331 |
Days Payable | 210 | 112 | 201 | 152 | 185 | 190 | 150 |
Cash Conversion Cycle | 407 | 331 | 242 | 456 | 368 | 357 | 306 |
Working Capital Days | 275 | 186 | 160 | 196 | 179 | 163 | 169 |
ROCE % | 27% | 25% | 32% | 21% | 26% | 28% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
14h - Of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR), Regulations 2015.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
20 Aug - Transcripts of the earning calls for the first quarter ended June 30, 2024 is enclosed herewith. kindly take the same into your records.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
12 Aug - Listing Obligation and Disclosure Requirements) Regulation, 2015, and further to our intimation dated August 07, 2024 to the Stock exchanges regarding Earning call in respect …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
10 Aug - Investor Presentation on financial results for the first quarter ended June 30, 2024, is enclosed Kindly take the above on records
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
10 Aug - Extract of the unaudited standalone and consolidated Financial Results for the first quarter ended June 30, 2024,as published in the below Newspaper on August 10, …
Concalls
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptPPT
-
Sep 2023Transcript PPT
Busines segments
A) APIs[1] Co manufactures API's through fermentation and semi-synthetic processes, across therapeutic areas of immunosuppressants, oncology, and anti-infectives
B) Formulations[2] which are used in therapeutic areas of immunosuppressants, nephrology and anti-infective drugs for critical care.